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Introduction
Botulin toxin (BTX), types A and B, is approved for the
treatment of a variety of disorders caused by muscle over-
activity [1]. An analgesic effect of BTX was observed
when treating movement disorders associated with pain;
serendipitous findings of its efficacy in headache were
observed when BTX was utilised to treat patients for
facial wrinkles with concomitant migraine [2].
Mechanism of action
BTX has different therapeutic mechanisms of action in
headache:
1. A direct effect at the neuromuscular junction, produc-
ing myorelaxation.
2. A direct antinociceptive effect on nerves in the face,
head and neck [3].
3. An indirect effect through the reduction of the central
sensitisation [4, 5].
Clinical experience
There are many published reports concerning efficacy
and safety of BTX in headache with different levels of
evidence (Table 1). BTX has shown varying degrees of
efficacy in the treatment of rare head and neck pain
(Table 2).
Concerning cluster headache and trigeminal neural-
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Abstract The authors discuss clini-
cal and international experience
about botulinum toxins (BTX types
A and B) in headache treatment.
Data from literature suggest good
results for the treatment of tension-
type headache, migraine and chron-
ic tension-type headache. In the
present paper mechanisms of action
and injection sites will also be dis-
cussed.
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gia, no controlled trials are available, although clinical
reports are published.
Patients and methods
The authors have been utilising BTX type A and type B for
headache since 1995. Patients were selected if they had headache
resistant to conventional pharmacological medications.
Three injection techniques were used:
1. fixed points;
2. “follow the pain”;
3. combination of both.
The procedures were followed by a muscle stretching pro-
gramme. Forty-one patients were submitted to repetition of proce-
dure. Patients were checked 2 and 4 months after the procedure.
Investigators, using a retrospective chart review, evaluated the
number of headache attacks per month, headache intensity and
drug consumption. Questions about quality of life were asked.
Results
To date 390 patients have been treated. They were 155
men and 235 women, with a mean age of 48 years (range
18–65 years). Patients suffered from:
a. chronic tension-type headache (296 patients, 75.9%);
b. chronic migraine (39 patients, 10%);
c. daily headache with drug abuse (47 patients, 12%);
d. other rare subtypes of headache (8 patients, 2%).
BTX type A was utilised in 374 patients (95.9%). The
mean dosage of BTX type A was 80 IU (range 50–100 IU)
for BOTOX or equivalent doses of other type of BTX.
Using a retrospective chart the number of headache
attacks per months, headache intensity and drug con-
sumption were recorded. Headache attacks per month
were reduced in 82% of patients. Eighty-five percent of
patients reported lower intensity of pain, 78% reduced
drug intake. These data are comparable to data published
by Blumenfeld [11]. No major side effects were reported.
Only four patients displayed mild and transient ptosis. Ten
patients complained of mild muscle weakness in the neck.
Discussion and conclusions
The inadequacy of current preventive treatment for dis-
abling primary headache makes new treatments, such as
Table 1 Published papers concerning primary headache and level of evidence
Author/year Primary headache type Patients, n Level 
of evidence
Smuts J et al., 1999 [6] Chronic tension-type headache 37 III
Binder et al., 2000 [7] Migraine 77 III
Silberstein et al., 2000 [8] Migraine 123 III
Barrientos and Chana, 2003 [9] Migraine 30 IB
Kaup et al., 2003 [10] Chronic tension-type headache 208 II
Blumenfeld A, 2003 [11] Migraine tension-type headache 271 II
Guyuron et al., 2002 [12] Migraine 29 III
Wheeler, 1998 [13] Migraine plus tension-type headache 4 IV
Klapper et al., 2000 [14] Migraine plus tension type headache 38 IB
Ondo et al., 2004 [15] Chronic migraine, chronic tension-type headache 60 IB
Table 2 Facial and neck pain, BTX use, and level of evidence
Author/year Type of pain Patients, n Level 
of evidence
Brin et al., 2003 [16] Cervical dystonia 170 V
Laubis-Heremann et al., 2002 [17] Cervical dystonia 31 II
Freund and Schwartz, 2000 [18] Chronic neck pain 30 IV
Wheeler et al., 2001 [19] Chronic neck pain 5 IV
Nixdorf et al., 2002 [20] Temporo-mandibular disorders 15 III
Schnider et al., 2002 [21] Cervicogenic headache 33 II
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BTX, an option. Preliminary clinical data are interesting,
however more detailed studies are needed to validate the
procedure. Selection of patients is essential, and technical
aspects are relevant. From the point of view of pharma-
coeconomics too, BTX treatment seems to be worth con-
sidering [22, 23].
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